Efficacy and Safety of 14-Day Vonoprazan-Based Dual Therapy Versus Quadruple Therapy for Helicobacter Pylori Eradication: A Multicentre, Non-Inferiority Randomized Controlled Trial

NCT07179159 · clinicaltrials.gov ↗

NA

Phase

RECRUITING

Status

372

Enrollment

OTHER

Sponsor class

Conditions

HELICOBACTER PYLORI INFECTIONS

Interventions

DRUG: 14-day vonoprazan-amoxicillin dual therapy
DRUG: 14-day vonoprazan-amoxicillin-levofloxacin-bismuth quadruple therapy
DRUG: 14-day vonoprazan-amoxicillin-clarithromycin-bismuth quadruple therapy

Sponsor

Yanqing Li

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]